<code id='5F94D71256'></code><style id='5F94D71256'></style>
    • <acronym id='5F94D71256'></acronym>
      <center id='5F94D71256'><center id='5F94D71256'><tfoot id='5F94D71256'></tfoot></center><abbr id='5F94D71256'><dir id='5F94D71256'><tfoot id='5F94D71256'></tfoot><noframes id='5F94D71256'>

    • <optgroup id='5F94D71256'><strike id='5F94D71256'><sup id='5F94D71256'></sup></strike><code id='5F94D71256'></code></optgroup>
        1. <b id='5F94D71256'><label id='5F94D71256'><select id='5F94D71256'><dt id='5F94D71256'><span id='5F94D71256'></span></dt></select></label></b><u id='5F94D71256'></u>
          <i id='5F94D71256'><strike id='5F94D71256'><tt id='5F94D71256'><pre id='5F94D71256'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:leisure time    - browse:66668
          Stock exchange
          Drew Angerer/Getty Images

          Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

          In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

          advertisement

          Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia